A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL).
Phase of Trial: Phase I/II
Latest Information Update: 23 Jul 2016
At a glance
- Drugs Obatoclax (Primary) ; Bortezomib
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 13 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.